Goldman downgraded HCA from Buy to Neutral and set a new price target of $271.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/15/2025 | $336.00 | Outperform → Neutral | Robert W. Baird |
| 12/17/2024 | $380.00 | Neutral | Analyst |
| 11/25/2024 | $400.00 → $320.00 | Equal Weight → Underweight | Wells Fargo |
| 11/22/2024 | Outperform → Mkt Perform | Raymond James | |
| 10/11/2024 | $475.00 | Overweight | KeyBanc Capital Markets |
| 9/3/2024 | $427.00 | Equal-Weight | Morgan Stanley |
| 5/30/2024 | $396.00 | Outperform | Robert W. Baird |
| 3/6/2024 | $356.00 | Overweight | Barclays |
SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)
SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)
SC 13G/A - HCA Healthcare, Inc. (0000860730) (Subject)
4 - HCA Healthcare, Inc. (0000860730) (Issuer)
HCA Healthcare, Inc. (NYSE:HCA) is scheduled to present at the following healthcare conferences: May 13, 2025 at 9:20am PT at the Bank of America 2025 Healthcare Conference. A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company's website, www.hcahealthcare.com. Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company's website for the latest information. About HCA Healthcare Nashville-based HCA Healthcare is one of the nation's leading providers of healthcare services comprising 192 hospitals and ap
HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the first quarter ended March 31, 2025. Key first quarter metrics (all percentage changes compare 1Q 2025 to 1Q 2024 unless otherwise noted): Revenues totaled $18.321 billion Net income attributable to HCA Healthcare, Inc. totaled $1.610 billion, or $6.45 per diluted share Adjusted EBITDA totaled $3.733 billion Cash flows from operating activities totaled $1.651 billion Same facility admissions increased 2.6 percent and same facility equivalent admissions increased 2.8 percent "The solid fundamentals we saw in our business the past several quarters continued into the first quarter of 2025," said
Computerized alerts tailored to each patient help identify which antibiotic is best suited to treat patients hospitalized with common infections in two 92-hospital trials. Two large multi-state studies funded by the National Institutes of Health and led by the University of California, Irvine, Harvard Pilgrim Health Care Institute, and HCA Healthcare have found a highly effective method to improve antibiotic selection for patients who are hospitalized with abdominal or skin and soft tissue infection to reduce their risk of antibiotic resistance. Results were published in JAMA Surgery and JAMA Internal Medicine and highlighted at the Congress of the European Society of Clinical Microbiology
10-Q - HCA Healthcare, Inc. (0000860730) (Filer)
8-K - HCA Healthcare, Inc. (0000860730) (Filer)
8-K - HCA Healthcare, Inc. (0000860730) (Filer)
HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the first quarter ended March 31, 2025. Key first quarter metrics (all percentage changes compare 1Q 2025 to 1Q 2024 unless otherwise noted): Revenues totaled $18.321 billion Net income attributable to HCA Healthcare, Inc. totaled $1.610 billion, or $6.45 per diluted share Adjusted EBITDA totaled $3.733 billion Cash flows from operating activities totaled $1.651 billion Same facility admissions increased 2.6 percent and same facility equivalent admissions increased 2.8 percent "The solid fundamentals we saw in our business the past several quarters continued into the first quarter of 2025," said
HCA Healthcare, Inc. (NYSE:HCA) announces the following Webcast: What: HCA Healthcare, Inc. 1Q 2025 Earnings Call When: Friday, April 25, 2025 at 9:00 AM Central (10:00 AM Eastern) How: Live Audio over the Internet: https://investor.hcahealthcare.com/events-and-presentations/default.aspx Contact: Frank Morgan, 615-344-2688, Vice President, Investor Relations, [email protected] If you are unable to listen during the live webcast, the call will be archived on the web site: https://investor.hcahealthcare.com/events-and-presentations/default.aspx. View source version on businesswire.com: https://www.businesswire.com/news/home/20250404757460/en/ INVESTOR CONTACT: Frank Morgan
HCA Healthcare, Inc. (NYSE:HCA) today announced financial and operating results for the fourth quarter ended December 31, 2024. Key fourth quarter metrics (all percentage changes compare 4Q 2024 to 4Q 2023 unless otherwise noted): Revenues totaled $18.285 billion Net income attributable to HCA Healthcare, Inc. totaled $1.438 billion, or $5.63 per diluted share (which includes an estimated $0.60 per diluted share unfavorable impact from Hurricanes Helene and Milton) Adjusted EBITDA totaled $3.712 billion Cash flows from operating activities totaled $2.559 billion Same facility admissions increased 3.0 percent and same facility equivalent admissions increased 3.1 percent "
Robert W. Baird downgraded HCA from Outperform to Neutral and set a new price target of $336.00
Analyst resumed coverage of HCA with a rating of Neutral and set a new price target of $380.00
Wells Fargo downgraded HCA from Equal Weight to Underweight and set a new price target of $320.00 from $400.00 previously
HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced that the HCA Healthcare Foundation has helped Girl Scouts of the USA (GSUSA) launch a new series of Mental Wellness Patch Programs to address mental wellness among girls in 4th through 12th grade. This is a result of the HCA Healthcare Foundation's $1.38 million grant to GSUSA, through its Healthier Tomorrow Fund, which was announced last year. "The HCA Healthcare Foundation has a long history of partnering with Girl Scouts nationally and locally. We are proud to deepen our partnership with Girl Scouts on this research-based mental wellness program," said Joanne Pulles, vice president of com
HCA Healthcare, Inc. (NYSE:HCA) today announced Jyric Sims, Ph.D., will become president of the company's West Florida Division, effective June 12. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230420005364/en/Jyric Sims, Ph.D. (Photo: Business Wire) Sims, who currently is CEO of HCA Healthcare's Medical City Plano and Medical City Frisco hospitals, will succeed Ravi Chari, M.D., who recently announced he will retire after 15 years with the company to pursue opportunities in early-stage healthcare companies. A more than 20-year healthcare veteran, Sims has been with HCA Healthcare since 2011. He has served as chief executive
HCA Healthcare, Inc. (NYSE:HCA), one of the nation's leading healthcare providers, today announced that Chuck Hall, HCA Healthcare's National Group president, will retire at the end of the year after nearly 36 years with the organization. Currently, Hall is responsible for HCA Healthcare's operations at 96 hospitals across 13 states. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005233/en/HCA Healthcare Announces Retirement of Longtime Senior Executive Chuck Hall (Photo: Business Wire) Over more than three decades, Hall has been influential in many successful initiatives that will benefit the company for years to come, inc
4 - HCA Healthcare, Inc. (0000860730) (Issuer)
4 - HCA Healthcare, Inc. (0000860730) (Issuer)
4 - HCA Healthcare, Inc. (0000860730) (Issuer)